After analysis and testing of 843 samples last month as part of random sampling, Central Drugs Standard Control Organization (CDSCO) declared 817 samples as standard quality (SQ) and 26 samples as not of standard quality (NSQ), spurious and misbranded.
Chennai, West Bengal, Madhya Pradesh, Bihar, Himachal Pradesh, Uttarakhand and Goa are those states in which the manufacturers of these drugs are based.
26 NSQ drugs include telmisartan tablets IP 40 MG (Telmiral 40) manufactured by Crescent Therapeutics Limited, Solan, Himachal Pradesh, amoxycillin and potassium clavulanate tablets IP (Clavage-1000) manufactured by Saitech Medicare Pvt Ltd, Himachal Pradesh, levocetirizine hydrochloride tablets IP 5 MG manufactured by Syncom Health Care Ltd, Dehradun, Uttarakhand, glimepiride tablets IP 3mg manufactured by Ravian Lifescience Pvt Ltd, Haridwar and alprazolam tablets manufactured by Medipol Pharmaceuticals India Pvt Ltd, Himachal Pradesh which failed the test for dissolution based on analysis done by Central Drugs Testing Laboratory (CDTL), Chennai, Regional Drugs Testing Laboratory (RDTL), Guwahati, RDTL, Chandigarh and Central Drugs Laboratory (CDL), Kolkata.
Many other drugs also failed tests for salicylic acid, bacterial endotoxins, particulate contamination etc. at different testing laboratories across the country.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like